Where will generic Paxlovid be produced?
The 35 companies that will produce versions of Paxlovid or its active ingredient are based in 12 different countries, according to the MPP. They include some of the world’s largest generic manufacturers, including Israel’s Teva Pharmaceutical Industries, India’s Sun Pharmaceutical Industries and US-based Viatris Inc.
Six of the companies will manufacture the drug’s main ingredient, nine plan to turn it into a finished product, and the remainder will do both.
Paxlovid is a two-drug treatment that combines a new compound, nirmatrelvir, with the older antiviral ritonavir, which is already available as a generic.
Pfizer will not receive royalties for the generic
The pharmaceutical company will not receive royalties from the sale of generic versions of its medicine while COVID-19 continues to be classified as a “Public Health Emergency of International Concern” by the WHO.
After the pandemic period, sales to low-income countries will continue to be royalty-free, lower-middle income countries and upper-middle income countries will be subject to a 5% royalty for sales to the public sector and 10% for the private sector, said the MPP.